Maze TherapeuticsMAZE
Recorded

Maze Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, everyone, and welcome to the Jefferies 2026 Global Healthcare Conference in London. It is my great pleasure to introduce Jason Coloma, CEO of Maze Therapeutics.

Jason ColomaCEO

Thank you. Hi, I am Jason Coloma. I am the CEO of Maze Therapeutics. First of all, I would like to thank the Jefferies team for having us at this year's conference. Just acknowledge our forward-looking statements. At Maze, our mission is to harness the power of human genetics to transform the lives of patients. For those not familiar with our story, we are a clinical-stage biopharmaceutical company focusing on novel small molecule precision medicines to diseases that have not seen it before, like chronic kidney disease. We have expected runway into 2029. We have multiple programs, multiple data catalysts coming, and the cash envelope to really be able to fund and deliver that for us and our shareholders. Extremely proud of the slide that you see here, as it represents all the hard work of our scientists and our team. We have been developing a best-in-class molecule in APOL1 kidney disease.

Jason ColomaCEO

For those not familiar with the disease, about 1 million individuals in the U.S. alone suffer from having the variant and potentially having kidney disease. There are at least 250,000 that have a high enough level of proteinuria where they can benefit from an APOL1 inhibitor. There are only three programs in development today. We are finishing our phase II HORIZON study. We have completed enrollment with data in early 2027. Another small molecule program, our SLC6A19 inhibitor, which we are developing for two indications, one in a rare metabolic disease called PKU, where we demonstrated, again, potential best-in-class properties relative to what has been described in the literature to date. That study is under enrolling as we speak, called CIPheR, and we expect to have data in 2027.

Jason ColomaCEO

We have also been developing the concept, as we are the first company to develop the genetic relationship of SLC inhibition in the context of chronic kidney disease, and we demonstrated proof of mechanism in an early development study. We are looking to launch that study in 2027, where we would like to show proteinuria reduction as well as be able to try to demonstrate for the first time the potential of a biomarker that might be able to be helpful in the development and identifying patients that might see a better effect size. We have had a very productive research engine over time.

Jason ColomaCEO

We have the ability to carry some of those programs forward ourselves, like we have with our APOL1 program, as well as our SLC program. We've also demonstrated the capability to have leverage through partnership, including our partnership with Shionogi, where we are developing our Pompe program and advancing that as they're completing the phase II enrollment. Based off of the cash that we've been able to raise, either through partnership or through equity financing, we do have the capital to fund all of these particular data catalysts that we've been describing, as well as be funded into 2029. I'd like to turn our attention to APOL1 kidney disease, as it is our lead program.

Jason ColomaCEO

Those that are not familiar with the kidney disease that's caused by APOL1, one thing is that most people associate chronic kidney disease or some form of kidney disease with an elderly population. It turns out APOL1 kidney disease affects a more younger generation of patients. They end up having more severe or progressive disease, meaning that they transition into end-stage renal disease and even into dialysis about 10 years earlier than those that don't have the variant. Unfortunately, as we know today, that standard of care, including things like ACE/ARBs and SGLT2 inhibitors, which are important for kidney disease treatment today, are very ineffective in being able to slow down the progression to end-stage renal disease.

Jason ColomaCEO

The idea of us, as well as other sponsors, was to identify a disease-modifying approach with APOL1 inhibition directly. If we're able to do that, we might be able to prevent not only the transition to end-stage renal disease, but hopefully that transition that they'll never have to enter dialysis ever in their life. How does APOL1 cause disease? What you can see on the diagram here on the left is that concept of being able to think about under certain conditions, what we know now today is that you have this overexpression of the APOL1 pore in the podocyte, which is basically a kidney cell. Under those conditions, what you can see there on those pairings of those particular pore is that they're ungated.

Jason ColomaCEO

Not only do you have basically these pores punching holes into cell membranes of those kidney cells, but they're also ungated such that they're causing this influx of the blue dots that you see here, which are these cations, causing eventually toxicity in the kidney. What is interesting is to think about how you might be able to have a disease-modifying therapy. What we realize is that at minimum, you want to be able to block the pore so that you don't have this influx of the cations causing the nephrotoxicity, but it also makes sense in the sense of understanding the biology that we might be able to prevent the formation of those pores from ever forming to begin with.

Jason ColomaCEO

That's what you see here on the right, is not only do we have the ability to block the pore, because we are a pore inhibitor, we have differentiated relative to any mechanism that's been described in the literature to date, the ability to disrupt the pore from forming. That's important because if you understand the biology, it turns out that APOL1 rapidly turns over in the podocyte, in the kidney cell, even less than 40 minutes. The idea is that you not only want to block it, but you want to disrupt assembly, and hopefully they never form to begin with. In terms of the patient population, we have a better understanding of the epidemiology, at least in the U.S. There's at least 1 million individuals that have the variant.

Jason ColomaCEO

With the number that you see here of at least 250,000 individuals, split up by the pie chart demonstrated here, those are the individuals that probably have a high enough proteinuria level, where an APOL1 inhibitor can reap clinical benefit. In terms of the split, FSGS, which is a pretty rare form of kidney disease, comprises some of those patients. More importantly, broad AMKD, both with or without diabetes, represents the large swath of opportunity as you think about the patient population. A disease that people have been following the kidney development area to probably a little bit more familiarity, IgA nephropathy, which is about 150,000-200,000 patients individual. What you see here in AMKD is less competition, so to speak, in the sense that there are no approved therapies. There is nothing. There are only three companies right now who are in later stage clinical development.

Jason ColomaCEO

The opportunity to develop what could be the first approved therapy creates an opportunity for us and as well as for the patients. We've completed enrollment in what we call our phase II study, which is the HORIZON study. If you see here on the top left, what we have is sort of the diagram that kind of describes what we're doing. We screen, so you have to have the variants of APOL1 that cause disease. You either have to be There's only two, fortunately. There's G1 and there's G2. So you have to be homozygous or have two copies of the G1 or G2, or you could be compound heterozygous, which just means you have one copy of each. Okay. We treat for three months, then we follow up for a month to see if the treatment effect is there.

Jason ColomaCEO

We've had the baseline cutoff at 200 mg/g UACR, the proteinuria level. What we're doing in HORIZON is really to be able to identify the patient populations beyond the rare FSGS, where there has been truly demonstrated proof of concept, that we might be able to incorporate in a later stage pivotal study. Could we include both the broader patient population, including those with or without diabetes? The endpoints are here, safety and tolerability. We've demonstrated to date, based off of our data and our information, a well-tolerated molecule. We'll look at, in terms of efficacy, UACR, which is basically the urinary albumin-to-creatinine ratio, which is a measure of how much protein is in the urine.

Jason ColomaCEO

What we want to be able to do is reduce that at least a certain percentage, at least 30% in terms of UACR reduction. In terms of our initial results, we had an administrative analysis that we had earlier this year, which really was to start to look at, one, do we have a competitive profile, in particular in FSGS patients? Secondarily, are there other patient populations beyond FSGS that we might want to incorporate and investigate in a more of a pivotal study? What we demonstrate is clear UACR reduction across a broad spectrum of patients. The data does clearly support the idea that it could be competitive in FSGS and maybe even in broader AMKD.

Jason ColomaCEO

I think what we saw is an initial signal in diabetes, albeit more modest, that we can look at, are there different particular enrichment strategies where we can better understand the patients who are responding to an APOL1 inhibitor in diabetes patients and consider those patients for an eventual pivotal study? The summary is outlined here, and I think just a couple things to kind of point. This is a once-a-day therapy as a concept. That's going to be important, in particular for cardiorenal patients. They tend to be what's called polypharm, meaning they're on more than one agent at a time. The idea that you have once-a-day convenient dosing will be important. We did show a good safety tolerability profile, both in our phase I and our initial phase II safety.

Jason ColomaCEO

We started to show the efficacy data across the entire cohort, one in FSGS showing what's been described as potentially best in class relative to what's been described in the literature to date at a certain percentage of UACR reduction. Broadly, what we want to be able to show across the entire HORIZON cohort and the whole entire study is at least a 30% reduction across all of the patients that are being explored in the study. If you note here, in particular, those that don't have diabetes are pretty dramatic reduction. If you look at this waterfall part in front of you, in terms of the amount of UACR reduction, this is just an administrative analysis of which we will have further and more patients in the full readout.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day